Synthesis of novel dopamine D2 / D3 receptor agonist for Parkinson's disease, D-512

Researchers at Binghamton University have developed a new drug that may limit the progression of Parkinson's disease while providing better symptom relief to potentially hundreds of thousands of people with the disease.

The following picture is the route of the compound (NovaChemistry).